Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Gains from Sales and Divestitures: 2024-2025

  • Janux Therapeutics' Gains from Sales and Divestitures rose 311.00% to $10,275 in Q3 2025 from the same period last year, while for Sep 2025 it was $10,275, marking a year-over-year increase of 311.00%. This contributed to the annual value of $2,500 for FY2024, which is N/A change from last year.
  • Per Janux Therapeutics' latest filing, its Gains from Sales and Divestitures stood at $10,275 for Q3 2025, which was up 311.00% from $2,500 recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Gains from Sales and Divestitures peaked at $10,275 during Q3 2025, and registered a low of $2,500 during Q3 2024.
  • Its 2-year average for Gains from Sales and Divestitures is $4,444, with a median of $2,500 in 2025.
  • Data for Janux Therapeutics' Gains from Sales and Divestitures shows a peak YoY skyrocketed of 311.00% (in 2025) over the last 5 years.
  • Over the past 2 years, Janux Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $2,500 in 2024, then spiked by 311.00% to $10,275 in 2025.
  • Its last three reported values are $10,275 in Q3 2025, $2,500 for Q2 2025, and $2,500 during Q4 2024.